Abstract Patients with treated phenylketonuria (PKU) can have subtle deficits in intellect, academic skills, and executive functioning. This study evaluates the relationship between intellectual outcome and concentration/variation in blood phenylalanine (Phe) during specific developmental periods (0-6 years, 7-12 years, >12 years) in our patients with PKU. Verbal comprehension, perceptual reasoning, and processing speed were used as measures of intelligence. Data were collected from 55 patients receiving treatment at
perceptual reasoning abilities using linear regression. Additionally, increased blood Phe concentration negatively impacted specific areas of verbal comprehension abilities for those 0-6 years of age (p=0.001). Variation of Phe levels around the mean (assessed as standard deviation) in each patient was associated with diagnostic (highest pretreatment) Phe levels and yearly median Phe levels (p<0.001 for both), but did not significantly impact intelligence in our group of patients. Frequent blood Phe monitoring from 7-12 years significantly reduced the probability of yearly median Phe exceeding 360 μM (p=0.005). Our data show that compliance with treatment in patients with PKU affects both the concentration and variation of blood Phe levels, and may have a greater impact on verbal comprehension and perceptual reasoning skills during the first 12 years of life when compared the influence beyond 12 years.
Abbreviation

IQ
Intelligence quotient OMIM Online Mendelian Inheritance in Man Phe Phenylalanine PKU Phenylketonuria SD standard deviation WAIS Wechsler Adult Intelligence Scale WISC Wechsler Intelligence Scale for Children Introduction Phenylketonuria (PKU, OMIM 261600) is a lifelong condition associated with increased phenylalanine levels, which can affect neuropsychological outcome (Waisbren et al. 2007; Burgard et al. 2009 ). PKU is treated primarily by diet, which alone, is variably effective in reducing associated comorbidities (Enns et al. 2010) . Recommended treatment range for blood Phe is between 120 and 360 μM up to 12 years of age and between 120 and 600 μM during adolescence (NIH 2000) . Lifelong continuation of dietary therapy is recommended for optimal outcomes (Wappner et al. 1999; NIH 2000) .
The neurodevelopmental consequences of elevated Phe are dependent on the age of occurrence and the duration of the exposure in patients with PKU (Antshel and Waisbren 2003) . Different areas of the brain mature on distinctive timelines during pre-and postnatal periods, since neuronal development in humans continues from early embryogenesis throughout adolescence (Rice and Barone 2000) . The mechanism by which elevated phenylalanine levels impair brain function is not completely understood, but hypotheses include impaired myelination, white matter lesions, and dopamine depletion in the prefrontal cortex (Dyer 2000; Feldmann et al. 2002; Gassio et al. 2005b; Anderson et al. 2007; White et al. 2010; Anderson and Leuzzi 2010) .
A meta-analysis by Waisbren et al. (2007) documented a proportional correlation between blood Phe during ages 0-12 years and 0-18 years with intelligence quotient (IQ). Early treated patients with PKU were predicted to have an average of a 2.6 point decrease in IQ for every 100 μM increase in blood Phe (calculated as mean Phe through both 12 and 18 years). In addition, each 100 μM increase in concurrent Phe was predictive of a 0.5 to 1.4 point decrease in IQ. A review of other longitudinal studies reported an approximate 7-point decrease in IQ for each 300 μM increase in blood Phe (or 2.3 IQ points for each 100 μM increase in blood Phe) for those less than 10 years of age (Burgard 2000) . A study by Anastasoaie et al. (2008) also suggests variability of blood Phe as a useful predictor of intelligence in PKU.
While severe mental retardation can be prevented with early and continuous treatment, multiple studies corroborate the presence of subtle deficits in intelligence, academic achievement, and executive functioning in early treated patients with PKU (Stemerdink et al. 2000; Moyle et al. 2007b) . These patients typically achieve average intelligence, but score lower than the general population (Fishler et al. 1987; Gassio et al. 2005b; Moyle et al. 2007a; Gentile et al. 2010; White et al. 2010) . Deficits specifically affect language skills, visual-spatial abilities, and processing speed, which may present with difficulties in reading, mathematics, spelling and slowed auditory comprehension (Chang et al. 2000; Brumm et al. 2004; Gassio et al. 2005a; Janzen and Nguyen 2010; Feillet et al. 2010) .
Patient compliance to dietary therapy tends to decrease after early childhood (Weglage et al. 1992; Walter et al. 2002; Channon et al. 2005) . Several collaborative PKU studies demonstrated a progressive increase in mean Phe levels in those above 4 years of age coinciding with decreased frequency of blood Phe monitoring (Smith and Beasley 1989; Wendel et al. 1990; Azen et al. 1996; Burgard et al. 1997) . In an observational study of 330 patients under 20 years of age, 30% of blood Phe levels were above the maximum recommended value in those less than 4 years, 50% in those 5 to 10 years, and 80% in those 15 to 19 years of age (Walter et al. 2002) . This study also reported 80% of those from 0-4 years and 5-9 years adhered to the recommended frequency of blood Phe testing compared to <75% of those aged 10-14 years and <50% in those 15-19 years.
The aim of the present study was to examine the relationship between the most recent measures of intelligence and the mean of yearly median Phe levels and mean standard deviation of blood Phe levels during specific developmental periods (0-6 years, 7-12 years, >12 years, and lifetime) in patients with PKU. Frequency of blood Phe monitoring during each developmental period was also assessed to determine the likelihood of achieving yearly median Phe within treatment range.
Methods
Subjects
The University of Utah Metabolic Clinic, Salt Lake City, UT, treats approximately 175 patients with PKU that reside in Utah, Idaho, and Wyoming. Data from 1980 to 2009 was collected from 55 patients that met the following inclusion criteria: (1) dietary treatment initiated within the first 30 days of life, (2) continuous treatment, (3) age above 5 years, (4) at least one cognitive evaluation, and (5) no maternal PKU (brain damage in utero caused by elevated maternal plasma Phe) or cognitive dysfunction from unrelated causes. This study was approved by the Institutional Review Board at the University of Utah.
Biochemical methods
Blood Phe concentrations were measured on filter paper using a bacterial inhibition assay until 1998, fluorometric techniques until 2006, after which they were measured by tandem mass spectrometry. Quantitative plasma amino acids were collected during clinic appointments and were analyzed by ion-exchange chromatography. The two different methods used to analyze Phe concentrations were comparable according to the validation performed at Associated Regional and University Pathologists (ARUP) laboratories that conduct newborn screening and plasma amino acid analysis for the state of Utah and in accord with previous publications (Gregory et al. 2007 ).
The quality of metabolic control during each developmental period was calculated as the mean of median blood Phe levels for all patients in 12-month intervals (Channon et al. 2005; Feldmann et al. 2002) . Yearly median blood Phe was chosen over the mean blood Phe, as the median corrects for fluctuations in blood Phe due to illness (Vilaseca et al. 2010) , though yearly median and mean Phe were similar and significantly correlated (p<0.001, r>0.9 for all age groups, not shown). Variability in blood Phe was calculated as the mean standard deviation of Phe for all patients in 12-month intervals. Mean number of blood Phe samples were also computed in 12-month intervals. Lifetime phenylalanine levels were calculated as the average of the yearly median Phe levels in each patient acquired prior to psychometric evaluation. Due to the known effect of concurrent Phe levels on cognitive testing performance (de Sonneville et al. 2010) , Phe concentrations at the time of psychometric evaluation or the average of two to four Phe levels within 6 months pre-and postevaluation were assessed. Diagnostic Phe, defined as highest pretreatment blood Phe concentration, was used to classify severity of PKU phenotype with levels >1200 μM as classic, 600-1200 μM as moderate, and 120-600 μM as mild PKU (Waisbren et al. 2007 ). This level was usually collected after 7 days of age, except in siblings of known patients in whom the proband's levels were used for classification. This classification correlated well with average intake of protein required to maintain blood phenylalanine levels within an acceptable range.
The University of Utah Metabolic Clinic advises patients with PKU to test blood Phe levels once weekly until one year of age, twice monthly until six years, and a minimum of monthly levels afterwards. Recommendations are modified based on patient adherence to dietary treatment. The advised therapeutic range at the Utah Metabolic Clinic is between 120 and 360 μM (NIH 2000), though there is no consensus on the optimal therapeutic range for different age groups among metabolic centers (Waisbren et al. 2007) .
Cognitive assessment
Measures of intelligence, including verbal comprehension, perceptual reasoning, and processing speed, were measured using the third and fourth editions of the Wechsler Intelligence Scale for Children (WISC-III and WISC-IV) and the third edition of the Wechsler Adult Intelligence Scale (WAIS-III). The standard at the University of Utah Metabolic Clinic is to complete cognitive testing on patients with PKU at ages 2, 6, 12, and 18 years.
Due to structural differences in the cognitive tests (Williams et al. 2003; Flanagan and Kaufman 2009) , certain indexes/subtests were excluded from analysis, including Full Scale IQ. Subtests and composite scores used for statistical analysis included Block Design, Symbol Search, and Verbal IQ (VIQ) or Verbal Comprehension Index (VCI). The Block Design and Symbol Search subtests have a mean of 10 and a standard deviation of 3. The VCI and Verbal IQ mean standard scores are 100 with a standard deviation of 15.
The Block Design subtest was used to assess perceptual reasoning abilities. It measures visual spatial reasoning and visual-constructional ability (Wechsler 2003) . The Symbol Search subtest specifically examines mental processing speed and accuracy (Wechsler 2003; Flanagan and Kaufman 2009 ). Subtests measuring perceptual reasoning and processing speed are consistent across the three tests; however, the composition of Verbal Comprehension Indexes vary. The WISC-III Verbal IQ contains Information, Similarities, Vocabulary, Arithmetic, and Comprehension subtests. The WISC-IV contains all but the Information and Arithmetic subtests, whereas the WAIS-III contains all but the Comprehension and Arithmetic subtests. The Comprehension Subtest measures social knowledge and awareness; the Information Subtest measures general knowledge; and the Arithmetic subtest is a measure of working memory and mental arithmetic (Kaufman and Lichtenberger 1999; Wechsler 2003) . Despite the differences in VCI subtests between the third and fourth editions of the WISC, they are highly correlated (r=0.87) (Flanagan and Kaufman 2009 ).
Statistical analysis
Subtest and index scores from the WISC-III, WISC-IVand the WAIS-III were compiled for statistical analysis. Descriptive statistics were obtained for sample characteristics and data related to blood Phe and cognitive testing. Pearson product moment correlations were computed between most recent measures of intelligence and treatment variables, which included diagnostic Phe level, days of life at which dietary therapy was initiated, concurrent Phe, yearly median Phe and mean SD Phe levels during each developmental period (0-6 years, 7-12 years, >12 years, and lifetime).
Treatment variables in the selected developmental periods were compared using paired t-tests. The age of participants included in the sample varied from 6 to 22 years of age. If the >12 year age group was further stratified, the number of samples in older age groups would not be sufficient for statistical analysis. In addition, Vilaseca et al. (2010) reported no significant difference in mean and standard deviation of blood Phe between 12-18 years and >18 years.
Multivariable logistic regression analysis examined the association between age (included as covariate and representing the developmental period), average number of Phe samples during each developmental period and yearly median Phe levels in each patient categorized as either Fig. 2 Changes of average yearly standard deviation blood phenylalanine levels with age (a), diagnostic phenylalanine levels (b), and lifetime yearly median Phe (c). a. The standard deviation blood Phe for each patient was averaged for every year and the average of all patients is reported as the mean±SD. c. Lifetime standard deviations of Phe levels were plotted against diagnostic (highest) Phe levels. c. Lifetime standard deviations of Phe levels were plotted against lifetime yearly median Phe levels within or outside the recommended treatment range for each age group. All statistical analyses were performed using SPSS version 18 for Windows software. A two-sided p-value of<0.05 was considered significant. Analyses are reported as mean±standard deviation. Table 1 summarizes the patients with phenylketonuria evaluated in this study. A total of 55 patients age 6 years or older had at least one evaluation of cognitive function. Twenty-seven patients were male and 28 were females. The mean age at most recent measure of IQ was 11.0±4.6 years. Average test scores were well within the normative sample range, with an average full scale IQ of 97.8±12.5, not significantly different from 100 and consistent with previous studies (Leuzzi et al. 2004; Gassio et al. 2005b; VanZutphen et al. 2007; Gentile et al. 2010) . Based on the diagnostic Phe level, 67.3% (n=37) were classified as having classic PKU (maximal [Phe] > 1200 μM), 18.2% (n=10) with moderate PKU ([Phe]= 600-1200 μM), and 14.5% (n=8) with mild PKU ([Phe]= 120-600 μM). The average Phe concentration concomitant with the time of psychometric evaluation was 592± 355 μM. All participants crossed age groups and contributed data for more than one developmental period, decreasing the number of participants with each subsequent age group. Analyses included a total of 7,484 blood Phe samples from all participants combined.
Results and discussion
Our results confirm that levels of phenylalanine progressively increase with age as patients with PKU adapt to a social life (Table 1, Fig. 1a) . Mean yearly median Phe levels were within the therapeutic range (120-360 μM) only from birth to 2 years of age. The increase in concentration of blood Phe levels from birth to 18 years clustered into three age groups (0-6 years, 7-12 years, >12 years of age) (Fig. 1a) . When data within each age group were combined, average yearly phenylalanine levels significantly increased from 365± 128 μM in patients aged 0-6 years to 530±209 μM in patients 7-12 years to 693±257 μM in those >12 years of age, which were statistically different when compared with paired t-tests (p<0.05 for all).
Concomitant with the increase in Phe levels, there was a reduced frequency of blood Phe monitoring as patients with PKU aged (Fig. 1b) . The mean number of yearly blood Phe samples did not meet the minimum recommended frequency of blood Phe testing at any age (advised frequency of testing was weekly from birth to 1 year, twice monthly from 1 to 6 years, and monthly afterward). It Table 2 Pearson product moment correlations between cognitive tests and treatment variables. For all correlations, the value of r is shown followed by the significance (p) within parenthesis should be noted that recommended frequency of testing is related to metabolic control. Patients with blood Phe levels consistently above treatment range are recommended to take more frequent levels compared to patients with good metabolic control. Recently, the variability of phenylalanine levels (assessed as standard deviation from the mean) was associated with changes in IQ in patients with PKU (Anastasoaie et al. 2008) . The average of the standard deviations of blood Phe levels in our patients did not significantly change over time (Fig. 2a) , indicating that there was no increased variability as patients aged. There was, however, wide variability among patients, explaining the large standard deviations (Fig. 2a) . The diagnostic Phe level was significantly correlated with the lifetime standard deviation of blood Phe (p<0.001, Fig. 2b ), suggesting that in our population, patients with a more biochemically severe PKU phenotype were more likely to have greater variability in blood Phe throughout life. In addition, there was a significant correlation between median lifetime Phe levels and standard deviation (p<0.001, Fig. 2c ), indicating again that compliance with treatment affected both parameters (Phe levels and its standard deviation).
Diagnostic Phe, days of life at which diet therapy was initiated, concurrent Phe, and mean standard deviation of Phe during all age groups were not associated with any measure of intelligence using Pearson product moment correlations (Table 2) . However, scores on the Block Design subtest, used to assess perceptual reasoning abilities, significantly correlated with yearly median Phe during 0-6 years, 7-12 years, and lifetime (Fig. 3) . The association was not significant for patients >12 years of age, possibly due to the low number of observations (Fig. 3c) . In our population, every 100 μM increase in yearly median Phe throughout the lifespan was associated with a 0.5-point decrease in Block Design scores (average score of 10 for general population), 0-6 years was associated with a 0.6-point decrease, and 7-12 years was associated with a 0.4-point decrease in scores (p=0.026; p=0.026; p=0.013, respectively). Additionally, perceptual reasoning scores were significantly lower in patients with yearly median Phe >360 μM compared to patients <360 μM from 7-12 years of age (p=0.008, Fig. 4 ) further suggesting that elevated yearly median Phe negatively impacts perceptual reasoning abilities. Visual-spatial and perceptual deficits negatively impact measures of mathematical skills, which may be misinterpreted as lower intelligence (Chang et al. 2000; Channon et al. 2009; Antshel 2010; Janzen and Nguyen 2010) . Our data, therefore, support previous studies showing that patients with early treated PKU score significantly lower on measures of mathematical skills compared to healthy controls (p<0.05) (Berry et al. 1979) .
Regression analysis revealed no appreciable association between verbal comprehension and verbal IQ scores (average score of 100 for general population) and yearly median Phe during any developmental period including lifetime (Table 2) . However, when WAIS-III scores were removed from the analysis leaving only the WISC-III and WISC-IV scores, yearly median Phe during 0-6 years and lifetime significantly predicted verbal comprehension scores (Fig. 5) . Every 100 μM increase in yearly median Phe measured throughout the lifespan was associated with a 3.5-point decrease in VCI/VIQ scores on the WISC-III and WISC-IV (p=0.011) and a 5.5-point decrease from 0-6 years (p=0.001). Analysis of WAIS-III scores only was not possible due to small sample size. This suggests the Comprehension subtest included in the WISC-III and WISC-IV may correlate more strongly with blood Phe levels than the Information subtest in the WAIS-III. The effects seen in our group of patients appear higher than those reported in other studies for full scale IQ (Burgard 2000; Waisbren et al. 2007 ). However, verbal comprehension and perceptual reasoning represent only a portion of the components of full scale IQ testing and they seem to be the most affected in our PKU population.
Speed of processing measured by the Symbol Search subtest was not associated with yearly median Phe or mean standard deviation of blood Phe during any developmental period (Table 2) . Brumm et al. (2004) found no significant association between current Phe levels and processing speed in adults as measured by the Trail-Making Test Part A. However, processing speed was significantly correlated with OR odds ratio, Phe phenylalanine, p significance, CI confidence interval
Age was included as a covariate in the regression model abnormal MRI scans, which are associated with elevated blood Phe (Solan 1987; Chang et al. 2000; Brumm et al. 2004; White et al. 2010) . While measures of processing speed were not sensitive to concentration or variability of blood Phe in our patients, deficits are commonly featured in early and continuously treated patients with PKU when compared to healthy controls (Cleary et al. 1995; Kaufman and Lichtenberger 1999; Channon et al. 2005; Moyle et al. 2007b; Janzen and Nguyen 2010) . Vilaseca et al. (2010) reported a significant difference (p<0.001) in index of dietary control (median Phe in 6-month intervals) between those with good (proportion of recommended samples was >90%), intermediate (>75%), and poor (<75%) frequency of testing. In our patient population, the mean number of blood Phe samples from 7-12 years significantly predicted the likelihood of maintaining yearly median Phe <360 μM after controlling for age using logistic regression analysis (Table 3) . Improved adherence to recommendations for testing frequency from 7-12 years of age on Phe levels produced an odds ratio of 0.556 (95% CI 0.369 to 0.836, p=0.005). Testing frequency from 0-6 years of age approached significance with an odds ratio of 0.852 (95% CI 0.721 to 1.007, p=0.06), indicating that increased frequency of blood Phe testing results in lower yearly median Phe.
There are limitations that may impact the interpretation of results from the present study. Participants were not selected randomly but were chosen from patients receiving treatment at the University of Utah Metabolic Clinic. Therefore, results may not reflect the characteristics of the entire population. Intelligence was measured with selected subtests of three different neuropsychological tests due to structural differences between measures rather than full scale IQ. Eliminating subtests from statistical analysis may not portray overall intelligence or compare to previous research measuring full scale IQ. There is also an increased risk of type 1 error due to small sample size, large number of exposure variables, and multiple comparisons.
In summary, our findings suggest an association between the quality of metabolic control during specific developmental periods and measures of intelligence. Appropriate blood Phe control during ages 0-6 years and 7-12 years may have a stronger association with perceptual reasoning abilities than other periods of life. Additionally, an increased blood Phe concentration may impact specific areas of verbal comprehension abilities for those 0-6 years of age. The importance of regular monitoring of blood Phe levels should be emphasized especially in those aged 7-12 years, as increased blood Phe monitoring decreases the probability that yearly median Phe will exceed the upper limit of the therapeutic range (360 μM). Our data do not support the hypothesis that variability in blood Phe may be a useful indicator of intelligence later in life, though a larger sample size might be required to find such an association.
